Health care venture capitalist, Lisa Suennen shared her take on what it would take to improve the situation. She recommends inexpensive new outpatient monitoring technologies, regulatory adjustments to encourage the system to play fair and more transparency in medical pricing, as well as patient education based of behavioral economics to help people take care of their own health.
"Mr. UDI" gave industry advice on complying with the complex unique device identification rules as medical device companies barrel toward the Sept. 24 deadline for adding identifiers to high-risk devices. Former FDA official Jay Crowley has acquired the nickname for his role in implementing and designing the UDI system. He is now a consultant for USDM Life Sciences.
The approval puts Gilead well on track to meet analyst expectations that Zydelig (idelalisib) will be hauling in $1.2 billion in annual sales by 2020, though there's little doubt Gilead will face pressure from European health agencies to keep a lid on the new drug's price.
Novo Nordisk picked up European approval for a combination of a long-acting insulin and its own Victoza, pioneering a once-a-day approach to Type 2 diabetes that could bring in blockbuster sales.
The U.S. District Court for the District of Columbia rejected the FDA's attempt to classify Prevor's Diphoterine Skin Wash as a drug rather than a device for the second time, dealing industry a victory in the sometimes contentious arena of product classification decisions.
Amid widespread safety concerns surrounding testosterone drugs, an FDA panel has recommended against Clarus Therapeutics' oral treatment, dimming the future for the company's sole product.
Companies have been studying Stendra for some sort of competitive edge. Now, they may have found one: The FDA backed the ED pill as a fast-acting treatment, taken 15 minutes before sex. Previously, the directions prescribed a 30-minute lead time.
Indian drug maker Natco has joined a long list of compatriots facing FDA concerns over manufacturing issues. According to The Financial Express, the company received an FDA Form 483 for a finished dosage plant in Telangana after an inspection in May.
An FDA advisory panel wants to limit the use of testosterone drugs for safety reasons--and the proposed restrictions would shrink sales significantly. That's not good news for AbbVie, the market leader, and other drugmakers that have been riding a surge of testosterone growth.
An expert panel assembled by the FDA has taken a big step toward blunting the fast-growing market for low-testosterone drugs, raising a thorny issue not just for the companies that sell such remedies, but also for two biotechs trying to gain approvals for new ones.